MD1105 is being developed as a disease-modifying therapy in Alzheimer’s disease (undisclosed molecule and mechanism of action). While currently in the pre-clinical phase, MedDay anticipates entering the clinic.

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel